Affymetrix to Repurchase $95.5M of Senior Notes as Part of Settlement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix has settled a legal dispute with holders of the company's 3.50 percent senior notes, and as part of the settlement it has agreed to start within two weeks a tender offer to repurchase the entire $95.5 million aggregate principal amount of the notes currently outstanding plus accrued interest, it said in a document filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.